← Back to Search

Diagnostic Testing for Pediatric Leukemia

Phase 1 & 2
Recruiting
Led By Michele S Redell
Research Sponsored by LLS PedAL Initiative, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be less than 22 years of age at the time of study enrollment
Known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trialaims to find better ways to diagnose and treat pediatric leukemias using clinical and biological data. Testing bone marrow may help doctors decide how to best treat patients.

Who is the study for?
This trial is for children, adolescents, and young adults under 22 with leukemia that's come back or is hard to treat. They must have consent from parents/guardians if needed, meet FDA and NCI human study requirements, and have specific types of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), mixed phenotype acute leukemia (MPAL), juvenile myelomonocytic leukemia (JMML), or relapsed ALL.
What is being tested?
The trial involves collecting bone marrow and blood samples from patients to understand the clinical and biological characteristics of their acute leukemias. This information may help determine eligibility for other sub-trials aimed at finding better ways to diagnose and treat pediatric leukemia.
What are the potential side effects?
Since this trial focuses on biospecimen collection rather than drug treatment, typical side effects associated with medications are not a concern here. However, there might be general discomforts related to sample collection such as pain or bruising at the needle site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am under 22 years old.
Select...
My leukemia linked to Down syndrome has returned or is not responding to treatment.
Select...
I have been diagnosed with juvenile myelomonocytic leukemia.
Select...
My AML cancer has returned or didn't respond to treatment.
Select...
My leukemia has returned or didn't respond to treatment.
Select...
I have AML or MDS that is new, has come back, or didn’t respond to treatment.
Select...
I have a new or returning myelodysplastic syndrome that is resistant to treatment.
Select...
My leukemia has returned after treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of patients with identification of a priori specified genomic and immunophenotypic targets who enroll on a sub-trial

Side effects data

From 2024 Phase 3 trial • 218 Patients • NCT00557193
70%
Alanine aminotransferase increased
58%
Mucositis oral
57%
Aspartate aminotransferase increased
57%
Febrile neutropenia
53%
Infections and infestations - Other, specify
48%
Neutrophil count decreased
33%
Hypokalemia
25%
Diarrhea
23%
White blood cell decreased
22%
Catheter related infection
22%
Anorexia
15%
Fever
15%
Platelet count decreased
13%
Dehydration
12%
Upper respiratory infection
12%
Skin infection
12%
Urinary tract infection
8%
Lung infection
8%
Skin ulceration
8%
Hypocalcemia
8%
Hyponatremia
7%
Alkaline phosphatase increased
7%
Anemia
7%
Weight loss
7%
Hyperglycemia
7%
Hypoglycemia
7%
Hypoxia
5%
Bronchial infection
5%
Enterocolitis infectious
5%
GGT increased
5%
Hypoalbuminemia
5%
Soft tissue infection
5%
Lymphocyte count decreased
5%
Skin and subcutaneous tissue disorders - Other, specify
3%
Sepsis
3%
Vomiting
3%
Pain
3%
Hypophosphatemia
3%
Pain of skin
3%
Oral pain
3%
Anaphylaxis
3%
Penile infection
3%
Erythema multiforme
2%
Blood and lymphatic system disorders - Other, specify
2%
Cardiac disorders - Other, specify
2%
Sinus tachycardia
2%
Irritability
2%
Scrotal infection
2%
Small intestine infection
2%
Fracture
2%
Wound complication
2%
Hyperkalemia
2%
Hypertriglyceridemia
2%
Generalized muscle weakness
2%
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
2%
Penile pain
2%
Pharyngeal mucositis
2%
Pleural effusion
2%
Stridor
2%
Dry skin
2%
Surgical and medical procedures - Other, specify
2%
Hypotension
2%
Acute kidney injury
2%
Anal mucositis
2%
Esophagitis
2%
Gastritis
2%
Nausea
2%
Bladder infection
2%
Wound infection
2%
Investigations - Other, specify
2%
Peripheral motor neuropathy
2%
Peripheral sensory neuropathy
2%
Epistaxis
2%
Pneumonitis
2%
Pulmonary edema
2%
Respiratory failure
2%
Hypertension
2%
Enterocolitis
2%
Acidosis
2%
Renal and urinary disorders - Other, specify
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm A (Standard Risk MLL-G)
Arm B (IR/HR MLL-R Chemotherapy)
Arm C (Efficacy/ Dose Level 2)
Induction (All Patients)
Post Induction (Follow-up Only)
Arm C (Safety/ Dose Level 1)
Arm C (Safety/ Dose Level 2)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Screening (biospecimen collection)Experimental Treatment1 Intervention
Patients undergo collection of blood and/or bone marrow samples at baseline, end of treatment cycle(s), and at relapse/refractory disease status (if applicable).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~2020

Find a Location

Who is running the clinical trial?

LLS PedAL Initiative, LLCLead Sponsor
3 Previous Clinical Trials
118 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,928 Previous Clinical Trials
41,017,078 Total Patients Enrolled
Children's Oncology GroupNETWORK
460 Previous Clinical Trials
239,038 Total Patients Enrolled

Media Library

Biospecimen Collection Clinical Trial Eligibility Overview. Trial Name: NCT04726241 — Phase 1 & 2
Myelodysplastic Syndrome Research Study Groups: Screening (biospecimen collection)
Myelodysplastic Syndrome Clinical Trial 2023: Biospecimen Collection Highlights & Side Effects. Trial Name: NCT04726241 — Phase 1 & 2
Biospecimen Collection 2023 Treatment Timeline for Medical Study. Trial Name: NCT04726241 — Phase 1 & 2
~429 spots leftby Dec 2026